Notice for ripretinib (Tudorrose Consulting Pty Ltd)
Active ingredients
ripretinib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of patients with advanced gastrointestinal stromal tumours (GIST), who have received prior treatment with imatinib, sumitinib and regorafenib.
Therapeutic area
Oncology